TheBioMLClinic

TheBioMLClinic

TheBioMLClinic

Frontier Engagements

Frontier Engagements

Frontier Engagements

Some programs are not troubleshooting a known problem. They are trying to do something the field has accepted ML cannot do.

Frontier Engagements are for programs operating at the boundary of what AAV-ML can currently address. The design space has no established computational path. The standard approaches were not built for what the program requires. The question itself is new.

This is not advisory. It is not a defined project with a known method. The scope emerges from the problem. The computational tools brought to it are built for gaps the field has left open, not because the biology is inaccessible, but because no one built the tools to reach them.

What I bring to a frontier engagement was developed independently, after and outside of any institutional affiliation. It does not incorporate any third party IPs.


This is the right conversation if —


  • Your program is trying to engineer a capsid that combines immune evasion, receptor targeting, cross-species function, or multi-trait constraints; and your team has concluded that no existing computational approach covers it.

  • You have a dataset no standard ML framework was designed to handle and you want to know whether signal can be extracted from it before committing to new experiments.

  • You are working with design constraints that push ML past the range where conventional training remains predictive.

  • Your question does not fit a defined project scope because the method does not exist yet.


When the engagement involves proprietary methodology

Some frontier problems require access to computational methodology that TheBioMLClinic holds as proprietary IP or trade secrets. For example, long-length sequence design, dual-loop engineering, and other components of the AAV Digital Twin 1.0. Not available through any existing platform, team, or CRO. As new methodology matures across Version 2.0 work, immunogenicity modeling, manufacturability prediction, translatability, additional opportunities will open. If your program is heading toward one of those problems, that conversation can start now.

When proprietary methodology is involved, the engagement takes one of two forms.

Co-development. TheBioMLClinic brings the computational framework and methodology. The partner brings biological data and experimental validation capacity. Outputs are jointly owned under defined terms.

Licensing. The partner accesses the methodology under structured terms. IP remains with TheBioMLClinic.

This is not for standard programs or early-stage companies. It is for partners whose programs have exhausted what existing tools can address.


This is the right conversation if —


  • Your program is trying to engineer a capsid that combines immune evasion, receptor targeting, cross-species function, or multi-trait constraints; and your team has concluded that no existing computational approach covers it.

  • You have a dataset no standard ML framework was designed to handle and you want to know whether signal can be extracted from it before committing to new experiments.

  • You are working with design constraints that push ML past the range where conventional training remains predictive.

  • Your question does not fit a defined project scope because the method does not exist yet.

When the engagement involves proprietary methodology


Some frontier problems require access to computational methodology that TheBioMLClinic holds as proprietary IP or trade secrets. For example, long-length sequence design, dual-loop engineering, and other components of the AAV Digital Twin 1.0. Not available through any existing platform, team, or CRO. As new methodology matures across Version 2.0 work, immunogenicity modeling, manufacturability prediction, translatability, additional opportunities will open. If your program is heading toward one of those problems, that conversation can start now.

When proprietary methodology is involved, the engagement takes one of two forms.

Co-development. TheBioMLClinic brings the computational framework and methodology. The partner brings biological data and experimental validation capacity. Outputs are jointly owned under defined terms.

Licensing. The partner accesses the methodology under structured terms. IP remains with TheBioMLClinic.

This is not for standard programs or early-stage companies. It is for partners whose programs have exhausted what existing tools can address.

If the method does not exist yet, the conversation starts with the problem, not the scope.

If you are working on a problem that existing tools cannot solve, this is worth a conversation.

— TheBioMLClinic


If the method does not exist yet, the conversation starts with the problem, not the scope.

The first conversation is about fit, not about selling.


— TheBioMLClinic